Jane Street’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $27.6M | Buy |
2,762,683
+2,140,076
| +344% | +$19.4M | ﹤0.01% | 1859 |
|
|
2026
Q1 | $5.93M | Sell |
622,607
-26,750
| -4% | -$208K | ﹤0.01% | 3259 |
|
|
2025
Q4 | $5.06M | Sell |
649,357
-1,198,989
| -65% | -$8.67M | ﹤0.01% | 3208 |
|
|
2025
Q3 | $14M | Buy |
1,848,346
+1,569,848
| +564% | +$13.1M | ﹤0.01% | 2015 |
|
|
2025
Q2 | $2.5M | Sell |
278,498
-207,311
| -43% | -$1.93M | ﹤0.01% | 4072 |
|
|
2025
Q1 | $3.64M | Sell |
485,809
-86,537
| -15% | -$698K | ﹤0.01% | 3405 |
|
|
2024
Q4 | $4.3M | Sell |
572,346
-139,079
| -20% | -$1.06M | ﹤0.01% | 2877 |
|
|
2024
Q3 | $5.41M | Sell |
711,425
-128,083
| -15% | -$974K | ﹤0.01% | 2726 |
|
|
2024
Q2 | $5.19M | Sell |
839,508
-277,170
| -25% | -$1.53M | ﹤0.01% | 2926 |
|
|
2024
Q1 | $5.67M | Buy |
1,116,678
+293,738
| +36% | +$1.65M | ﹤0.01% | 2454 |
|
|
2023
Q4 | $4.93M | Buy |
822,940
+204,334
| +33% | +$1.18M | ﹤0.01% | 2872 |
|
|
2023
Q3 | $4.38M | Buy |
618,606
+190,826
| +45% | +$1.37M | ﹤0.01% | 2797 |
|
|
2023
Q2 | $3.01M | Buy |
427,780
+153,255
| +56% | +$1.23M | ﹤0.01% | 3487 |
|
|
2023
Q1 | $2.29M | Sell |
274,525
-20,417
| -7% | -$197K | ﹤0.01% | 3584 |
|
|
2022
Q4 | $3.39M | Buy |
294,942
+227,003
| +334% | +$2.83M | ﹤0.01% | 3033 |
|
|
2022
Q3 | $856K | Sell |
67,939
-98,619
| -59% | -$1.27M | ﹤0.01% | 5693 |
|
|
2022
Q2 | $1.76M | Buy |
166,558
+68,523
| +70% | +$707K | ﹤0.01% | 4397 |
|
|
2022
Q1 | $1.59M | Sell |
98,035
-155,683
| -61% | -$2.5M | ﹤0.01% | 5177 |
|
|
2021
Q4 | $3.51M | Buy |
253,718
+30,037
| +13% | +$398K | ﹤0.01% | 3419 |
|
|
2021
Q3 | $3.21M | Sell |
223,681
-2,095
| -0.9% | -$33K | ﹤0.01% | 3529 |
|
|
2021
Q2 | $3.57M | Sell |
225,776
-166,297
| -42% | -$2.26M | ﹤0.01% | 3243 |
|
|
2021
Q1 | $3.99M | Buy |
392,073
+162,313
| +71% | +$1.67M | ﹤0.01% | 2751 |
|
|
2020
Q4 | $1.71M | Buy |
229,760
+139,132
| +154% | +$717K | ﹤0.01% | 3767 |
|
|
2020
Q3 | $311K | Buy |
90,628
+45,917
| +103% | +$197K | ﹤0.01% | 5827 |
|
|
2020
Q2 | $213K | Sell |
44,711
-3,003
| -6% | -$12K | ﹤0.01% | 6290 |
|
|
2020
Q1 | $95K | Buy |
47,714
+31,344
| +191% | +$86.3K | ﹤0.01% | 4953 |
|
|
2019
Q4 | $56K | Sell |
16,370
-360
| -2% | -$906 | ﹤0.01% | 4900 |
|
|
2019
Q3 | $48K | Sell |
16,730
-1,541
| -8% | -$4.79K | ﹤0.01% | 4893 |
|
|
2019
Q2 | $69K | Buy |
+18,271
| New | +$110K | ﹤0.01% | 4915 |
|
|
2018
Q1 | – | Sell |
-27,549
| Closed | -$135K | – | 4797 |
|
|
2017
Q4 | $135K | Buy |
+27,549
| New | +$133K | ﹤0.01% | 4301 |
|
|
2016
Q2 | – | Sell |
-33,348
| Closed | -$94K | – | 4050 |
|
|
2016
Q1 | $94K | Buy |
33,348
+15,811
| +90% | +$70.1K | ﹤0.01% | 3897 |
|
|
2015
Q4 | $181K | Buy |
+17,537
| New | +$174K | ﹤0.01% | 3649 |
|
|
2014
Q4 | – | Sell |
-17,114
| Closed | -$167K | – | 2473 |
|
|
2014
Q3 | $167K | Sell |
17,114
-89,687
| -84% | -$1.1M | ﹤0.01% | 2269 |
|
|
2014
Q2 | $1.36M | Sell |
106,801
-73,659
| -41% | -$717K | 0.02% | 723 |
|
|
2014
Q1 | $1.91M | Buy |
+180,460
| New | +$1.92M | 0.02% | 594 |
|
|
2013
Q4 | – | Sell |
-181,665
| Closed | -$1.32M | – | 2339 |
|
|
2013
Q3 | $1.32M | Buy |
181,665
+126,569
| +230% | +$642K | 0.02% | 852 |
|
|
2013
Q2 | $85K | Buy |
+55,096
| New | +$95K | ﹤0.01% | 2470 |
|
Other funds holding BCRX
RCM
DM
TCM
PA
JT
VPC
Jane Street's BCRX Position: Q2 2026 in Review
Jane Street increased its BioCryst Pharmaceuticals (BCRX) stake by 344% in Q2 2026, buying an estimated $19.4M and bringing the position to 2,762,683 shares worth $27.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1859.
Jane Street first reported a position in BCRX in Q2 2013 and has held it in 37 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Jane Street held 2,762,683 shares of BioCryst Pharmaceuticals worth $27.6M as of Q2 2026.
- Jane Street bought 2,140,076 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
- BioCryst Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #1859 holding.
- Jane Street first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.